This study from the Jacksonville group reported outcomes of 31 pediatric patients with salivary gland tumors treated with PT. At a median follow-up of 7.5 years, OS was 96%, and local control was 94%. There were no nodal recurrences. Acute toxicities were limited to mucositis requiring opioids and transient Grade 3 dermatitis. The most serious occurred in three patients requiring hearing aids, one with chronic otitis media, one with osteonecrosis of the mastoid, and one with external canal stenosis. There was neither Grade 4 toxicity nor second malignancy. The authors concluded that moderate-dose PT delivered to smaller volumes resulted in excellent long-term disease control and limited toxicity in children with common salivary gland tumors.